| 证券代码：000876 | 证券简称：新希望 公告编号：2026-05 | | --- | --- | | 债券代码：127049 | 债券简称：希望转 2 | 新希望六和股份有限公司 关于向特定对象发行 A 股股票预案等相关文件修订情况 说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 新希望六和股份有限公司（以下简称"新希望"或"公司"） 2024 年第一次临时股东大会、2025 年第二次临时股东会、第九届董 事会第二十二次会议、第九届董事会第三十次会议、第十届董事会第 四次会议审议通过了公司向特定对象发行 A 股股票相关的议案。 2026 年 1 月 12 日，公司召开第十届董事会第十次会议，审议通 过了《关于调整公司向特定对象发行 A 股股票方案的议案》等与本次 发行相关的议案。结合公司内部经营改善情况及未来三年的资金情况， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 证券发行注册管理办法》等相关法律、法规及规范性文件的规定，公 司对本次向特定对象发行 A 股股票方案进行部分调整。 一、发行方案调整具体内容 1、募集资 ...

证券代码：000876 证券简称：新希望 公告编号：2026-07 债券代码：127049 债券简称：希望转 2 新希望六和股份有限公司 关于最近五年被监管部门和交易所采取处罚 或监管措施的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 鉴于新希望六和股份有限公司（以下简称"公司"）拟向特定 对象发行 A 股股票，现根据相关要求，公司将最近五年被证券监管 部门和交易所采取处罚或监管措施及整改的情况公告如下： 一、最近五年被证券监管部门和交易所处罚的情况 公司最近五年不存在被证券监管部门和交易所处罚的情况。 二、最近五年被证券监管部门和交易所采取监管措施的情况 及相应整改措施 针对上述情况，公司进行了整改，具体措施如下： 公司在收到监管函后，公司及全体董事、监事、高级管理人员 高度重视，组织相关人员系统地认真学习了相关法律、法规及监管 规则，后续公司及相关人员将坚决遵循上市公司信息披露规范要求， 持续加强对《深圳证券交易所股票上市规则》《上市公司信息披露 管理办法》以及其他相关法律、法规的学习，进一步规范公司运作， 切实履行信息披露义务，不断提高公司信息披 ...

本次会议由董事以传真方式会签，审议并通过了如下议案： （一）审议通过了"关于公司符合向特定对象发行 A 股股票条件 的议案" 债券代码：127049 债券简称：希望转 2 证券代码：000876 证券简称：新希望 公告编号：2026-04 新希望六和股份有限公司 第十届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 新希望六和股份有限公司（以下简称"公司"）第十届董事会第十 次会议通知于 2026 年 1 月 11 日以电子邮件方式通知了全体董事。第 十届董事会第十次会议于 2026 年 1 月 12 日以通讯表决方式召开。本 次会议应参加表决董事 9 人，实际表决董事 9 人，会议的召开及表决 程序符合有关法律、行政法规、部门规章、规范性文件和公司《章程》 的规定，所作决议合法有效。 二、董事会会议审议情况 表决结果：9 票同意，0 票反对，0 票弃权。 为充实公司资本实力，优化公司资产结构，提高抗风险能力，公 司拟向特定对象发行A股股票。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司证券 ...

Group 1 - The aquaculture sector saw a slight increase of 0.04% on January 12, with Fucheng Co. leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index closed at 14366.91, up by 1.75% [1] - Fucheng Co. had a closing price of 6.35, with a significant increase of 10.05%, and a trading volume of 370,100 shares, amounting to a transaction value of 227 million yuan [1] Group 2 - The aquaculture sector experienced a net outflow of 233 million yuan from main funds, while retail investors saw a net inflow of 250 million yuan [2] - The trading data indicates that major stocks like Wens Foodstuff Group and Muyuan Foods had slight declines in their stock prices, with Wens closing at 17.05, down by 0.41% [2] - Fucheng Co. reported a net outflow of 50.99 million yuan from main funds, despite its overall price increase [3]

Group 1 - The core viewpoint of the articles indicates that the feed raw material prices are expected to rise significantly in 2025, with corn, soybean meal, and rapeseed meal increasing by over 10%, 9%, and 8% respectively, while the market dynamics show differentiation in trends [1][2] - In 2025, the total production of pig feed is projected to recover, with a year-on-year increase of 9.0% in April, driven by a rebound in breeding demand, while the market is characterized by regional differentiation and concentration among leading producers [3] - Major feed companies are expected to maintain robust profitability in 2025, with Hai Da Group reporting a net profit of 2.639 billion yuan in the first half of the year, a year-on-year increase of 24.16%, and New Hope Liuhe achieving a net profit of 755 million yuan, a significant increase of 162% [4] Group 2 - For 2026, the supply side anticipates corn production to exceed 300 million tons, with soybean imports remaining above 100 million tons, while the demand side expects stable total feed production around 330 million tons, indicating a slowdown in growth due to a reduction in breeding capacity [5] - At the beginning of 2026, major companies are expected to implement price increases of 50-100 yuan per ton for various feed products, driven by rising raw material costs and the need to ensure product quality [6] - The price dynamics in early 2026 show a two-round price increase driven by rising raw material costs, with the first round occurring in December 2025 and the second round at the beginning of 2026, influenced by seasonal stocking demands [7]

Core Viewpoint - The pig price in December 2025 reached a new low, with the industry experiencing a prolonged period of price inversion, indicating ongoing challenges in the market [1][2]. Group 1: Market Performance - The December 2025 pig sales data revealed that the expected peak season did not materialize, with average sales prices dropping over 25% year-on-year, ranging between 11 CNY/kg and 12 CNY/kg [2]. - Major companies like Muyuan Foods reported a 14.75% decrease in sales volume to 6.98 million pigs in December, resulting in a 36.06% decline in sales revenue to 9.667 billion CNY [2]. - Some companies, such as Zhengbang Technology, saw significant increases in sales volume, with a 73.26% rise to 1.0286 million pigs and a 25.75% increase in revenue to 914 million CNY [2]. Group 2: Price Trends - The pig price exhibited a fluctuating trend in December, with a brief recovery mid-month due to seasonal demand, but ultimately ended with a slight month-on-month decline [3]. - The average price of white strip pork decreased by 26.21% year-on-year, despite a 15.22% increase in daily slaughter volume, indicating persistent downward pressure on prices [3]. Group 3: Capacity Reduction - The industry is gradually initiating capacity reduction, but the pace remains slow, with many companies still maintaining high levels of breeding sows [4]. - As of December 2025, Muyuan Foods reported a breeding sow inventory of 3.232 million heads, reflecting a decrease, but overall industry capacity reduction is not yet substantial [4]. - Analysts suggest that the current high levels of breeding sow inventory will continue to exert pressure on supply, limiting price recovery potential [4]. Group 4: Future Outlook - Industry experts predict that the effects of capacity reduction will become evident in the second half of 2026, with the first half expected to remain in a downward price cycle [5].

Core Viewpoint - The approval and clinical application of the new generation TRK inhibitor, Zolacotrine (Yinoxin, ICP-723), marks a significant breakthrough in China's broad-spectrum anti-cancer drug development, providing better treatment options for patients with NTRK fusion-positive solid tumors [1][3]. Group 1: Drug Development and Approval - Zolacotrine is the first domestically developed TRK inhibitor approved for clinical use in China, with prescriptions already issued in multiple hospitals [1][3]. - The drug addresses unmet clinical needs for patients with NTRK fusion-positive tumors, which are prevalent in over 26 types of solid tumors [4]. Group 2: Clinical Efficacy - Clinical studies show Zolacotrine has a total response rate (ORR) of 89.1%, with a disease control rate (DCR) of 96.4%, and a 24-month progression-free survival rate (PFS) of 77.4% [5]. - The drug demonstrates a total survival rate (OS) of 90.8%, indicating its potential to provide long-term relief for patients [5]. Group 3: Safety and Administration - Zolacotrine has a low rate of treatment-related adverse events leading to permanent discontinuation, at only 0.4%, enhancing patient compliance [7]. - The once-daily oral administration of Zolacotrine offers convenience for long-term treatment [7]. Group 4: Overcoming Resistance - Zolacotrine effectively overcomes resistance issues associated with first-generation TRK inhibitors, maintaining strong inhibitory activity against common mutations in the TRK kinase domain [9]. Group 5: CNS Penetration - The drug's unique molecular structure allows it to effectively penetrate the blood-brain barrier, achieving a 100% objective response rate in intracranial lesions, thus providing comprehensive protection for patients with brain metastases [10]. Group 6: Company Perspective - The CEO of the company expressed gratitude towards regulatory bodies, clinical experts, and partners for their support in the development and launch of Zolacotrine, emphasizing its role in improving the quality of life for cancer patients [12].

新华社记者 姜 帆摄影报道 1月5日，次仁拉姆(左三)和家人在新居前合影。 震后3天，有关部门迅速启动灾后恢复重建总体方案编制；3月初，灾后重建启动。当记者2025年10月再 次见到次仁拉姆时，她的新家已建成交付，她也再次怀孕，预产期在12月。"小孩出生的时候，我们就 已经住进新房子了。"她满怀希冀地说。 如今，地震灾难过去一年，次仁拉姆的小女儿央金拉姆出生已满一个月，而地震时她抱在怀里一个多月 大的婴儿格桑巴宗已经可以下地跑了。新居、新生命给家庭带来新希望。 1月5日，次仁拉姆怀抱已满月的女儿央金拉姆。 1月5日，次仁拉姆在新居中陪大女儿玩耍。 西藏定日县长所乡通来村，年轻的母亲次仁拉姆在2025年1月7日的6.8级地震中失去了一个3岁的孩子。 ...

Core Insights - The data from the National Cancer Center indicates that over 350,000 new breast cancer cases were reported in China in 2022, posing a significant threat to women's health [1] - The implementation of the new medical insurance directory on January 1, 2026, will include 8 new drugs for breast cancer and expand the indications for 2 existing drugs, increasing access to innovative treatments for more patients [1] Group 1 - The most common molecular subtype of breast cancer is HR+/HER2- (hormone receptor positive, HER2 negative), accounting for approximately 80% of all breast cancer patients [1] - Endocrine therapy, including targeted endocrine drugs, is crucial for both early and late-stage breast cancer patients, as highlighted by experts in the field [1] Group 2 - Resistance to endocrine therapy is often linked to the activation of the PAM pathway, particularly mutations in genes such as PIK3CA and AKT, which limit subsequent treatment options for patients [2] - The inclusion of targeted PAM pathway drugs in the medical insurance directory significantly reduces the financial burden on patients, making innovative treatments more accessible [2] Group 3 - Early detection and timely diagnosis of different clinical subtypes of breast cancer, along with personalized treatment plans, can significantly extend survival time and improve the quality of life for patients [3] - A multidisciplinary treatment approach is essential for breast cancer management, integrating evidence-based medicine, expert experience, and patient preferences to enhance treatment outcomes and optimize resource utilization [3]

主线一：生猪养殖--产能去化逐步深化，静待周期拐点 我们认为生猪养殖行业的供需格局向好，短期生猪供过于求趋势持续，预计在 26 年上半年仍将给猪价带来 压 力，行业性亏损持续。价格磨底与亏损是无形的手，政策引导产能调控是有形的手，二者有机结合，产能 去化将 逐步深化，26 年下半年供应压力将逐步缓解，需求端相对平稳，预计行业供需格局持续向好。近期建 议关注能繁 母猪存栏去化及疫病情况。 非洲猪瘟后，生猪养殖结构出现变化，表现为规模化程度快速提升和短期养户增多， 受此影响行业产能变动 表现为难涨难跌的窄幅波动，对应生猪供需矛盾减弱，在养殖正常出栏的情况下，猪价波 动幅度收窄。我们 认为，成本是猪企能否实现行业超额收益和长期成长的核心要素，并且成本因素在周期下行期 的重要性尤为 突出。在未来几年，猪企表现将有明显分化，具备成本优势的企业有望维持温和扩张，而落后产能 将被进一 步淘汰。 我们认为，板块估值低位具备安全性，26 年板块基本面持续向好静待拐点，头部企业估值有 望修复，成本优 势明显的头部企业长期投资的价值属性提升，重点推荐头部猪企牧原股份，其他受益标的德康农 牧、温氏股 份、神农股份、天康生物等也有望受 ...